This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nimmanapalli, R. Articles by Bhalla, K. N. Search for Related Content PubMed PubMed Citation Articles by Nimmanapalli, R. Articles by Bhalla, K. N.

Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels

Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612 [R. N., C. L. P., E. O., K. N. B.], and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136 [M. O., D. N.]

We have demonstrated that Apo-2 ligand (Apo-2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis of human prostate cancer PC-3, DU145, and LNCaP cells in a dose-dependent manner, with PC-3 cells displaying the greatest sensitivity to Apo-2L/TRAIL. Susceptibility of the prostate cancer cell types to Apo-2L/TRAIL-induced apoptosis did not appear to correlate with the levels of the Apo-2L/TRAIL receptors death receptor (DR) 4 (TRAIL receptor 1) or DR5 (TRAIL receptor 2), decoy receptor (DcR) 1 and DcR2, Flame-1, or the inhibitors of apoptosis proteins family of proteins. Apo-2L/TRAIL-induced apoptosis of PC-3 cells was associated with the processing of caspase-8, caspase-10, and the proapoptotic Bid protein, resulting in the cytosolic accumulation of cytochrome c as well as the processing of procaspase-9 and procaspase-3. Cotreatment with the caspase-8 inhibitor z-IETD-fmk or DR4: Fc significantly inhibited Apo-2L/TRAIL-induced apoptosis. Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to 8-fold) without affecting the protein levels of DcR1 and DcR2, Apo-2L/TRAIL, Fas, or Fas ligand. Up-regulation of DR4 and DR5 was not preceded by the induction of their mRNA levels but was inhibited by cotreatment with cycloheximide. Importantly, sequential treatment of PC-3, DU145, and LNCaP cells with paclitaxel followed by Apo-2L/TRAIL induced significantly more apoptosis than Apo-2L/TRAIL treatment alone (P < 0.01). This was also associated with greater processing of procaspase-8 and Bid, as well as greater cytosolic accumulation of cytochrome c and the processing of caspase-3. These findings indicate that up-regulation of DR4 and DR5 protein levels by treatment with paclitaxel enhances subsequent Apo-2L/TRAIL-induced apoptosis of human prostate cancer cells.

This article has been cited by other articles:

				A. Ashkenazi, P. Holland, and S. G. Eckhardt Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL) J. Clin. Oncol., July 20, 2008; 26(21): 3621 - 3630. [Abstract] [Full Text] [PDF]

				M. Kim, J. Liao, M. L. Dowling, K. R. Voong, S. E. Parker, S. Wang, W. S. El-Deiry, and G. D. Kao TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells Cancer Res., May 1, 2008; 68(9): 3440 - 3449. [Abstract] [Full Text] [PDF]

				P. G. Oliver, A. F. LoBuglio, K. R. Zinn, H. Kim, L. Nan, T. Zhou, W. Wang, and D. J. Buchsbaum Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11 Clin. Cancer Res., April 1, 2008; 14(7): 2180 - 2189. [Abstract] [Full Text] [PDF]

				D. A. Sallman, X. Chen, B. Zhong, D. L. Gilvary, J. Zhou, S. Wei, and J. Y. Djeu Clusterin mediates TRAIL resistance in prostate tumor cells Mol. Cancer Ther., November 1, 2007; 6(11): 2938 - 2947. [Abstract] [Full Text] [PDF]

				S. Baritaki, A. Katsman, D. Chatterjee, K. C. Yeung, D. A. Spandidos, and B. Bonavida Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation J. Immunol., October 15, 2007; 179(8): 5441 - 5453. [Abstract] [Full Text] [PDF]

				D. Deeb, H. Jiang, X. Gao, S. Al-Holou, A. L. Danyluk, S. A. Dulchavsky, and S. C. Gautam Curcumin [1,7-Bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] Sensitizes Human Prostate Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand/Apo2L-Induced Apoptosis by Suppressing Nuclear Factor-{kappa}B via Inhibition of the Prosurvival Akt Signaling Pathway J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 616 - 625. [Abstract] [Full Text] [PDF]

				J. Gong, D. Yang, S. Kohanim, R. Humphreys, L. Broemeling, and R. Kurzrock Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies Mol. Cancer Ther., December 1, 2006; 5(12): 2991 - 3000. [Abstract] [Full Text] [PDF]

				H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Yoshida, T. Sakai, T. Koyano, T.-S. Kam, K. Murata, et al. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells Blood, January 15, 2006; 107(2): 679 - 688. [Abstract] [Full Text] [PDF]

				K. G. Drosopoulos, M. L. Roberts, L. Cermak, T. Sasazuki, S. Shirasawa, L. Andera, and A. Pintzas Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway J. Biol. Chem., June 17, 2005; 280(24): 22856 - 22867. [Abstract] [Full Text] [PDF]

				L. Xia, D. Chen, R. Han, Q. Fang, S. Waxman, and Y. Jing Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells Mol. Cancer Ther., March 1, 2005; 4(3): 381 - 388. [Abstract] [Full Text] [PDF]

				S.-J. Park, C.-H. Wu, J. D. Gordon, X. Zhong, A. Emami, and A. R. Safa Taxol Induces Caspase-10-dependent Apoptosis J. Biol. Chem., December 3, 2004; 279(49): 51057 - 51067. [Abstract] [Full Text] [PDF]

				Y.-Y. Wu, Y.-C. Chang, T.-L. Hsu, S.-L. Hsieh, and M.-Z. Lai Sensitization of Cells to TRAIL-induced Apoptosis by Decoy Receptor 3 J. Biol. Chem., October 15, 2004; 279(42): 44211 - 44218. [Abstract] [Full Text] [PDF]

				S.-H. Kim, K. Kim, J. G. Kwagh, D. T. Dicker, M. Herlyn, A. K. Rustgi, Y. Chen, and W. S. El-Deiry Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells J. Biol. Chem., September 17, 2004; 279(38): 40044 - 40052. [Abstract] [Full Text] [PDF]

				J. Sonnemann, V. Gekeler, A. Sagrauske, C. Muller, H.-P. Hofmann, and J. F. Beck Down-regulation of protein kinase C{eta} potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells Mol. Cancer Ther., July 1, 2004; 3(7): 773 - 781. [Abstract] [Full Text] [PDF]

				F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Y. Li, S. Wittmann, L. Moscinski, P. Atadja, and K. Bhalla Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells Cancer Res., April 1, 2004; 64(7): 2580 - 2589. [Abstract] [Full Text] [PDF]

				X. Liao, L. Zhang, J. B. Thrasher, J. Du, and B. Li Glycogen synthase kinase-3{beta} suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer Mol. Cancer Ther., November 1, 2003; 2(11): 1215 - 1222. [Abstract] [Full Text] [PDF]

				J. An, Y.-P. Sun, J. Adams, M. Fisher, A. Belldegrun, and M. B. Rettig Drug Interactions between the Proteasome Inhibitor Bortezomib and Cytotoxic Chemotherapy, Tumor Necrosis Factor (TNF) {alpha}, and TNF-Related Apoptosis-Inducing Ligand in Prostate Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4537 - 4545. [Abstract] [Full Text] [PDF]

				T. R. Singh, S. Shankar, X. Chen, M. Asim, and R. K. Srivastava Synergistic Interactions of Chemotherapeutic Drugs and Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand on Apoptosis and on Regression of Breast Carcinoma in Vivo Cancer Res., September 1, 2003; 63(17): 5390 - 5400. [Abstract] [Full Text] [PDF]

				D. J. Buchsbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter, and A. F. LoBuglio Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model Clin. Cancer Res., September 1, 2003; 9(10): 3731 - 3741. [Abstract] [Full Text] [PDF]

				I. Petrache, A. Birukova, S. I. Ramirez, J. G. N. Garcia, and A. D. Verin The Role of the Microtubules in Tumor Necrosis Factor-{alpha}-Induced Endothelial Cell Permeability Am. J. Respir. Cell Mol. Biol., May 1, 2003; 28(5): 574 - 581. [Abstract] [Full Text] [PDF]

				A. F. Taghiyev, N. V. Guseva, H. Harada, C. M. Knudson, O. W. Rokhlin, and M. B. Cohen Overexpression of BAD Potentiates Sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Treatment in the Prostatic Carcinoma Cell Line LNCaP Mol. Cancer Res., May 1, 2003; 1(7): 500 - 507. [Abstract] [Full Text] [PDF]

				S. Wang, Z. Wang, P. Dent, and S. Grant Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells Blood, May 1, 2003; 101(9): 3648 - 3657. [Abstract] [Full Text] [PDF]

				J. Asakuma, M. Sumitomo, T. Asano, T. Asano, and M. Hayakawa Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel Cancer Res., March 15, 2003; 63(6): 1365 - 1370. [Abstract] [Full Text] [PDF]

				W. C. Reinhold, H. Kouros-Mehr, K. W. Kohn, A. K. Maunakea, S. Lababidi, A. Roschke, K. Stover, J. Alexander, P. Pantazis, L. Miller, et al. Apoptotic Susceptibility of Cancer Cells Selected for Camptothecin Resistance: Gene Expression Profiling, Functional Analysis, and Molecular Interaction Mapping Cancer Res., March 1, 2003; 63(5): 1000 - 1011. [Abstract] [Full Text] [PDF]

				T. M. LaVallee, X. H. Zhan, M. S. Johnson, C. J. Herbstritt, G. Swartz, M. S. Williams, W. A. Hembrough, S. J. Green, and V. S. Pribluda 2-Methoxyestradiol Up-Regulates Death Receptor 5 and Induces Apoptosis through Activation of the Extrinsic Pathway Cancer Res., January 15, 2003; 63(2): 468 - 475. [Abstract] [Full Text] [PDF]

				D. Deeb, Y. X. Xu, H. Jiang, X. Gao, N. Janakiraman, R. A. Chapman, and S. C. Gautam Curcumin (Diferuloyl-Methane) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in LNCaP Prostate Cancer Cells Mol. Cancer Ther., January 1, 2003; 2(1): 95 - 103. [Abstract] [Full Text] [PDF]

				J. Strater, U. Hinz, H. Walczak, G. Mechtersheimer, K. Koretz, C. Herfarth, P. Moller, and T. Lehnert Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter Clin. Cancer Res., December 1, 2002; 8(12): 3734 - 3740. [Abstract] [Full Text] [PDF]

				G. H. Yoo, M. P. Piechocki, J. F. Ensley, T. Nguyen, J. Oliver, H. Meng, D. Kewson, T. Y. Shibuya, F. Lonardo, and M. A. Tainsky Docetaxel Induced Gene Expression Patterns in Head and Neck Squamous Cell Carcinoma Using cDNA Microarray and PowerBlot Clin. Cancer Res., December 1, 2002; 8(12): 3910 - 3921. [Abstract] [Full Text] [PDF]

				M. A. Eid, R. W. Lewis, and M. V. Kumar Mifepristone Pretreatment Overcomes Resistance of Prostate Cancer Cells to Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand (TRAIL) Mol. Cancer Ther., August 1, 2002; 1(10): 831 - 840. [Abstract] [Full Text] [PDF]

				M. Fu, C. Wang, J. Wang, X. Zhang, T. Sakamaki, Y. G. Yeung, C. Chang, T. Hopp, S. A. W. Fuqua, E. Jaffray, et al. Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans-Repression Function Mol. Cell. Biol., May 15, 2002; 22(10): 3373 - 3388. [Abstract] [Full Text] [PDF]

				F. Guo, R. Nimmanapalli, S. Paranawithana, S. Wittman, D. Griffin, P. Bali, E. O'Bryan, C. Fumero, H. G. Wang, and K. Bhalla Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis Blood, May 1, 2002; 99(9): 3419 - 3426. [Abstract] [Full Text] [PDF]

				Y. Huang, Q. He, M. J. Hillman, R. Rong, and M. S. Sheikh Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells Cancer Res., September 1, 2001; 61(18): 6918 - 6924. [Abstract] [Full Text] [PDF]